Leguy, Soizic
Lefort, Mathilde
Lescot, Lucile
Michaud, Audrey
Vukusic, Sandra
Le Page, Emmanuelle
Edan, Gilles
Kerbrat, Anne
Lebrun-Frenay, Christine
De Sèze, Jérôme
Laplaud, David-Axel
Wiertlewski, Sandrine
Leray, Emmanuelle
Michel, Laure http://orcid.org/0000-0002-8119-7794
Funding for this research was provided by:
Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
Article History
Received: 10 March 2022
Revised: 2 June 2022
Accepted: 3 June 2022
First Online: 23 June 2022
Declarations
:
: LM received honoraria as speaker from Biogen, Merck Serono, BMS Celgene, Sanofi Genzyme, Roche, and Novartis. SV reports consulting and lecture fees, travel grants and research support from Biogen, Celgène, Novartis, Merck, Roche, Sanofi Genzyme and Teva Pharm. DAL has received consulting and lecturing fees, travel grants and unconditional research support from Biogen, Genzyme, Novartis, Merck, Roche, Sanofi, Medday, Teva Pharma and BMS. SW received honoraria as speaker or consultant from Alexion, Biogen, Merck Serono, Roche, and Novartis. ELP received honoraria for lectures or consulting from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, TEVA, Roche, Alexion. SL, ML, LL, AM, GE, AK, JDS, CLF, EL have no no conflict of interest regarding this work.
: All procedures performed this study were in accordance with the ethical standards of the institutional and national research committee. The present study received approval from the Comité de Protection des Personnes on April 16th 2019 (registration number SI: 19.03.05.63609) and was declared to the Agence Nationale de Sécurité du Médicament et des produits de santé (ID RCB:2019-A00567-50).